Lycopene lipid nanoparticles as well as preparation method and application thereof

By encapsulating lycopene in lipid nanoparticles, using sodium caseinate or whey protein to improve stability, the problem of degradation of lycopene in environmental factors and low bioavailability is solved, and its function is achieved Efficient application and safety in food.

CN119033104APending Publication Date: 2024-11-29LIAOCHENG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411168217.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Lycopene is prone to oxidation and degradation and cis-trans isomerization under environmental factors such as light, oxygen, and heat, resulting in changes in its physical and chemical properties and low bioavailability, limiting its application in functional foods.

Method used

Lycopene is encapsulated in lipid nanoparticles, mixed lycopene, lecithin and cholesterol, dissolved and dried into a film by adding organic solvent, and then hydrated in buffer solution, using high-pressure homogenization method or liposomes Extrusion method reduces particle size and uses sodium caseinate or whey protein to improve stability.

Benefits of technology

It significantly improves the solubility and bioavailability of lycopene, reduces its toxicity to normal cells, expands its application range in functional foods, and enhances its antioxidant ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033104A_ABST
    Figure CN119033104A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of functional food, and particularly relates to lycopene lipid nanoparticles as well as a preparation method and application thereof.The preparation method of the lycopene lipid nanoparticles comprises the following steps: mixing lycopene, lecithin and cholesterol, adding an organic solvent for dissolving, and drying to form a film; after treatment, a buffer solution is added for hydration, and the lycopene lipid nanoparticles are obtained. The lycopene is encapsulated in the lipid nanoparticles, so that the lycopene is kept in a highly dispersed state and exists in an amorphous state, the solubility of the lycopene in water can be remarkably improved, and the bioavailability of the lycopene is improved. Meanwhile, the stability and the oxidation resistance of the lycopene are improved, and the effect of the lycopene is guaranteed; the toxicity to normal cells is reduced, and the application range is expanded. The lecithin, the sodium caseinate and the whey protein used in the invention have strong emulsifying ability and solubility and high stability, and are widely applied to the field of functional foods.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of functional foods, and specifically relates to lycopene lipid nanoparticles and a preparation method and application thereof. Background Art

[0002] Bioactive substances have a variety of potential health benefits, such as improving health and preventing diseases, and therefore have received extensive attention from scientific researchers in recent years. However, these ingredients are subject to various limitations in industrial applications, such as poor water solubility, sensitivity to environmental factors such as light, high temperature, and oxygen, and low oral bioavailability. Lycopene, as a highly effective antioxidant bioactive substance, plays an important role in preventing cancer and cardiovascular diseases. However, due to the presence of a large number of unsaturated bonds in its structure, it is prone to oxidative degradation and cis-trans isomerization under environmental factors such as light, oxygen, and heat, which significantly affects its physical and chemical properties. In addition, its hydrophobicity and low bioavailability further limit its widespread application. Therefore, researchers have designed a variety of formulation strategies to efficiently load lycopene, including polymer nanoparticles, liposomes, nanoemulsions, or inclusion complexes. This effectively reduces the degradation of lycopene and controls its release, thereby improving its bioavailability.

[0003] Among them, liposomes have great potential in improving the bioavailability of bioactive substances and promoting the development of nutritious foods. However, due to its thermodynamic instability, it cannot protect the loaded drugs well during storage, so there are certain limitations in its application. By adding additional excipients, such as polysaccharides (such as gelatin and alginate) and proteins (such as sodium caseinate and whey protein isolate), lipid nanoparticles can be prepared to effectively improve their colloidal stability. The particle size of lipid nanoparticles is in the range of 10-1000nm, which is consistent with liposomes in physical structure, thermodynamic properties and formation mechanism, but its particle size is smaller and the stability is better, so it can deliver bioactive substances more effectively.

[0004] Sodium caseinate is the most commonly used form of casein in the food industry. It has high emulsifying ability and plays a positive role in improving the stability of lipid nanoparticles when used as a surfactant. Whey protein is separated from milk during the cheese-making process and is a high-quality protein source with high biological value, high protein utilization, and rich in essential amino acids and branched-chain amino acids. The benefits of whey protein include muscle growth / maintenance, immune regulation, anti-inflammation, and weight control. Therefore, it is urgent to provide a product that can effectively reduce the degradation of lycopene and control its release, improve its bioavailability, and expand its application range. Summary of the invention

[0005] The purpose of the present invention is to provide a lycopene lipid nanoparticle and a preparation method and application thereof. The present invention encapsulates lycopene in lipid nanoparticles to keep lycopene in a highly dispersed state and in an amorphous state, which can significantly improve the solubility of lycopene in water, improve its bioavailability and reduce cytotoxicity.

[0006] The objective of the present invention is achieved through the following technical solutions:

[0007] The present invention provides a method for preparing lycopene lipid nanoparticles, comprising the following steps:

[0008] (1) mixing lycopene, lecithin and cholesterol, adding an organic solvent to dissolve the mixture, and drying the mixture to form a film;

[0009] (2) After the treatment in step (1), a buffer solution is added for hydration to obtain the lycopene lipid nanoparticles.

[0010] Furthermore, in step (1), during the mixing process, the molar ratio of lycopene, lecithin and cholesterol is 1:15-25:5-8.3.

[0011] Furthermore, in step (1), the organic solvent includes any one of anhydrous ethanol or acetone.

[0012] Furthermore, in step (1), the dissolution process is assisted by ultrasound, the temperature of the ultrasound is 23-27° C., and the power is 200-300W.

[0013] Furthermore, in step (1), the drying and film forming is performed by rotary evaporation drying at 40-60° C. and a rotation speed of 100 rpm.

[0014] Furthermore, in step (2), the buffer solution is a blank PBS solution, a PBS solution containing sodium caseinate, or a PBS solution containing whey protein.

[0015] Furthermore, the parameters of the buffer solution are pH 7.4, 10 mM.

[0016] Furthermore, in step (2), the step of reducing the particle size of the lipid nanoparticles by high pressure homogenization or liposome extrusion is also included.

[0017] The present invention also provides lycopene lipid nanoparticles prepared by the preparation method.

[0018] The present invention also provides an application of the lycopene lipid nanoparticles in preparing food and / or health products for improving health and preventing diseases.

[0019] The beneficial effects of the present invention are:

[0020] The present invention encapsulates lycopene in lipid nanoparticles, so that the lycopene remains in a highly dispersed state and exists in an amorphous state, which can significantly increase the solubility of lycopene in water, improve its bioavailability, and at the same time improve the stability and antioxidant capacity of lycopene to ensure the efficacy of lycopene; and reduce its toxicity to normal cells, thereby expanding its application range.

[0021] The lecithin, sodium caseinate and whey protein used in the present invention have strong emulsifying ability and solubility, high stability and are widely used in the field of functional foods. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0023] Figure 1 TEM images of lycopene liposomes (A) and lipid nanoparticles (B) in Experimental Example 2 of the present invention;

[0024] Figure 2 The DSC spectra of different preparations in Experimental Example 3 of the present invention, wherein a: lycopene; b: lecithin; c: cholesterol; d: sodium caseinate; e: lycopene liposomes; f: lycopene lipid nanoparticles;

[0025] Figure 3 DPPH scavenging ability diagram of different preparations in Test Example 4 of the present invention;

[0026] Figure 4 This is a diagram for evaluating the cytotoxicity of different preparations in Test Example 5 of the present invention. DETAILED DESCRIPTION

[0027] The embodiments of the present invention are described in detail below, and the embodiments are intended to explain the present invention and should not be construed as limiting the present invention. If specific techniques or conditions are not specified in the embodiments, they are carried out according to the techniques or conditions described in the literature in this area or according to the product specifications. If the manufacturers of reagents or instruments are not specified, they are all conventional products that can be obtained commercially.

[0028] In order to have a clearer understanding of the technical features, purposes and effects of the present invention, the specific implementation methods of the present invention are now described.

[0029] The preparation method of lycopene lipid nanoparticles of the present invention comprises the following steps:

[0030] Lycopene, lecithin and cholesterol are mixed (molar ratio: 1:15-25:5-8.3), organic solvent (anhydrous ethanol or acetone) is added to dissolve (ultrasound is also used during the dissolution process, the ultrasound temperature is 23-27°C, and the power is 200-300W), and dried to form a film (the drying method is rotary evaporation drying, the drying temperature is 40-60°C, and the rotation speed is 100rpm), and buffer solution (the buffer solution is blank PBS (pH 7.4, 10mM), PBS solution containing sodium caseinate or whey protein (pH 7.4, 10mM)) is added to hydrate to obtain lycopene lipid nanoparticles.

[0031] The present invention adopts a high-pressure homogenization method / liposome extrusion method to reduce the particle size of lipid nanoparticles.

[0032] The following examples are used to further illustrate the present invention, but are not intended to limit the present invention.

[0033] Example 1

[0034] This embodiment 1 provides a method for preparing sodium caseinate-stabilized lycopene lipid nanoparticles by a thin film method, comprising the following steps:

[0035] Lycopene, lecithin, and cholesterol (molar ratio 1:25:8.3) were weighed in proportion, placed in an eggplant-shaped flask and dissolved with 5 mL of anhydrous ethanol, and slowly rotary evaporated in a 40°C water bath to form a film. Subsequently, 30 mL of pH 7.4 buffer solution dissolved with sodium caseinate (SC) was added to the eggplant-shaped flask and vortexed vigorously until the film was completely hydrated; finally, the lycopene / sodium caseinate lipid nanoparticles (Lips-LYC / SC NPs) with small particle size and uniform dispersion were obtained by homogenization in a high-pressure homogenizer for 45 minutes.

[0036] Example 2

[0037] This embodiment 2 provides a method for preparing whey protein-stabilized lycopene lipid nanoparticles by a thin film method, comprising the following steps:

[0038] Lycopene, lecithin, and cholesterol (molar ratio 1:25:8.3) were weighed in proportion, placed in an eggplant-shaped flask and dissolved with 5 mL of anhydrous ethanol, and slowly rotary evaporated in a 40°C water bath to form a film. Subsequently, 30 mL of pH 7.4 buffer solution with whey protein (WPI) was added to the eggplant-shaped flask and vortexed vigorously until the film was completely hydrated; finally, the lycopene / whey protein lipid nanoparticles (Lips-LYC / WPI NPs) with small particle size and uniform dispersion were obtained by homogenization in a high-pressure homogenizer for 45 minutes.

[0039] Embodiment 3:

[0040] This embodiment 3 provides a method for preparing lycopene liposomes by a thin film method, comprising the following steps:

[0041] Lycopene, lecithin, and cholesterol (molar ratio 1:25:8.3) were weighed in proportion, placed in an eggplant-shaped flask and dissolved with 5 mL of anhydrous ethanol, and slowly rotary evaporated in a 40°C water bath to form a film. Subsequently, 30 mL of pH 7.4 blank buffer was added to the eggplant-shaped flask and vortexed vigorously until the film was completely hydrated; finally, the lycopene liposomes (LYC Lips) with small particle size and uniform dispersion were obtained by homogenization in a high-pressure homogenizer for 45 minutes.

[0042] Test Example 1

[0043] The particle size, PDI and potential of Lips-LYC / SC NPs, Lips-LYC / WPI NPs and LYC Lips prepared in Examples 1-3 were measured by dynamic light scattering, and each sample was measured 3 times. The encapsulation efficiency of lycopene was determined by ultrafiltration centrifugation, and the storage stability of LYC Lips, Lips-LYC / SC NPs and Lips-LYC / WPI NPs at 4°C was investigated.

[0044] The characterization of specific liposomes and lipid nanoparticles is shown in Table 1. It can be seen from Table 1 that the particle size (Dh) of lycopene liposomes and lipid nanoparticles is uniform and the roundness is good (the polydispersity index PDI is small). After the addition of protein, the size of the lipid nanoparticles is smaller and the encapsulation efficiency is higher. The two lipid nanoparticles are basically stable after 5 days, and the lycopene lipid nanoparticles (Lips-LYC / SC NPs) with sodium caseinate as a stabilizer have better stability.

[0045] Table 1 Characterization of liposomes and lipid nanoparticles

[0046]

[0047] Test Example 2

[0048] The morphology of the liposomes and lipid nanoparticles prepared in Examples 1 and 3 was observed using a transmission electron microscope. The sample was diluted a certain multiple, dropped onto a copper grid, and then counterstained with a 2% uranyl acetate solution after drying. The morphology was observed under an accelerating voltage.

[0049] from Figure 1 It can be seen that the morphology of liposomes and lipid nanoparticles both present a uniform spherical structure with a particle diameter of about 100 nm. Both particles have good dispersibility and no aggregation, but the particle size of lipid nanoparticles is slightly smaller than that of liposomes.

[0050] Test Example 3

[0051] The liposomes and lipid nanoparticles prepared in Examples 1 and 3 were freeze-dried to obtain solid samples, and the DSC curves of the liposomes and lipid nanoparticles were analyzed using a differential scanning calorimeter. The test was performed in a temperature range of 20-200°C and a heating rate of 10°C / min.

[0052] from Figure 2 It can be seen that the free lycopene peaks at 173.54°C, indicating that it has a specific melting point (Tm) or crystalline state. No peaks related to lycopene were observed in the DSC spectra of liposomes and lipid nanoparticles. These results indicate that lycopene is stably encapsulated in lipid nanoparticles in an amorphous state, which is of great significance for improving its bioavailability.

[0053] Test Example 4

[0054] Free lycopene and different lycopene preparations prepared in Examples 1 and 3 were diluted with PBS, and the final concentrations of lycopene were 10, 15, 30, 50 and 100 μg / mL, respectively. The free radical scavenging ability of lycopene preparations of different concentrations was tested according to the instructions of the DPPH kit.

[0055] from Figure 3 It can be seen that lycopene preparations with different concentrations have significantly higher antioxidant capacity than free lycopene with the same concentration, and their antioxidant capacity is dose-dependent, indicating that different dosage forms can improve the antioxidant activity of lycopene. The enhancement of the antioxidant activity of different preparations is due to the improvement of the dispersibility of lycopene and the increase in the probability of interaction between lycopene molecules and DPPH free radicals. Therefore, improving the dispersibility of lycopene is an effective way to improve the antioxidant capacity of lycopene.

[0056] Test Example 5

[0057] The in vitro cytotoxicity evaluation of free lycopene and the liposomes and lipid nanoparticles prepared in Examples 1 and 3 was performed as follows:

[0058] Normal human hepatocytes (LO2) were seeded in 96-well plates (5×10 3 Cells / well), after culturing for 24 hours, different concentrations of LYC preparations were added to each well and cultured for 24 hours. After the culture was completed, MTT solution (20 μL, 5 mg / mL) was added and incubated for 4 hours. After discarding the liquid in the 96-well plate, DMSO (150 μL) was added and shaken for 5 minutes to ensure that the formazan crystals were fully dissolved. Cells without drug treatment were used as controls, and the absorbance of different samples at 490 nm was measured using an ELISA instrument to calculate the cell survival rate (%).

[0059] from Figure 4It can be seen that within the lycopene concentration range (5-150 μg / mL), lycopene liposomes have a certain cytotoxicity to LO2 cells, and are concentration-dependent. The LO2 survival rate is less than 70% at high concentrations. Free lycopene and lycopene lipid nanoparticles showed no cytotoxicity, and their cell survival rate basically reached 90%. This shows that sodium caseinate-modified lipid nanoparticles can effectively reduce cytotoxicity and have higher safety.

[0060] It can be seen from the above embodiments that the present invention provides a lycopene lipid nanoparticle, which can keep lycopene in a highly dispersed state and exist in an amorphous state, can significantly improve the solubility of lycopene in water, improve its bioavailability, and at the same time improve the stability and antioxidant capacity of lycopene, ensure the efficacy of lycopene, and reduce its toxicity to normal cells, thereby expanding the application range of lycopene and having broad application value.

[0061] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution of the present invention, which should be covered by the scope of the claims of the present invention.

Claims

1. A method for preparing lycopene lipid nanoparticles, characterized in that: The following steps are involved: (1) mixing lycopene, lecithin and cholesterol, adding an organic solvent to dissolve the mixture, and drying the mixture to form a film; (2) After the treatment in step (1), a buffer solution is added for hydration to obtain the lycopene lipid nanoparticles.

2. The method for preparing lycopene lipid nanoparticles according to claim 1, characterized in that: In step (1), during the mixing process, the molar ratio of lycopene, lecithin and cholesterol is 1:15-25:5-8.

3.

3. The method for preparing lycopene lipid nanoparticles according to claim 1, characterized in that: In step (1), the organic solvent includes either anhydrous ethanol or acetone.

4. The method for preparing lycopene lipid nanoparticles according to claim 1, characterized in that: In step (1), the dissolution process is assisted by ultrasound, the temperature of the ultrasound is 23-27° C., and the power is 200-300W.

5. The method for preparing lycopene lipid nanoparticles according to claim 1, characterized in that: In step (1), the drying and film forming is performed by rotary evaporation drying at 40-60° C. and a rotation speed of 100 rpm.

6. The method for preparing lycopene lipid nanoparticles according to claim 1, characterized in that: In step (2), the buffer solution is a blank PBS solution, a PBS solution containing sodium caseinate, or a PBS solution containing whey protein.

7. The method for preparing lycopene lipid nanoparticles according to claim 6, characterized in that: The parameters of the buffer were pH 7.4, 10 mM.

8. The method for preparing lycopene lipid nanoparticles according to claim 1, characterized in that: In step (2), the method further includes the step of reducing the particle size of the lipid nanoparticles by using a high-pressure homogenization method or a liposome extrusion method.

9. Lycopene lipid nanoparticles prepared by the preparation method according to any one of claims 1 to 8.

10. Use of the lycopene lipid nanoparticles according to claim 9 in the preparation of food and / or health products for improving health and preventing diseases.